Abstract:Background: Intermediate cells are present in the early stages of human prostate development and adenocarcinoma. While primary cells isolated from benign human prostate tissues or tumors exhibit an intermediate phenotype in vitro, they cannot form tumors in vivo unless genetically modified. It is unclear about the stem cell properties and tumorigenicity of intermediate cells. Methods: We developed a customized medium to culture primary human intermediate prostate cells, which were transplanted into male immunodeficient NCG mice to examine tumorigenicity in vivo. We treated the cells with different concentrations of dihydrotestosterone (DHT) and enzalutamide in vitro and surgically castrated the mice after cell transplantation in vivo. Immunostaining, qRT-PCR, RNA sequencing, and western blotting were performed to characterize the cells in tissues and 2D and 3D cultures. Results: We found intermediate cells expressing AR+PSA+CK8+CK5+ in the luminal compartment of human prostate adenocarcinoma by immunostaining. We cultured the primary intermediate cells in vitro, which expressed luminal (AR+PSA+CK8+CK18+), basal (CK5+P63+), intermediate (IVL+), and stem cell (CK4+CK13+PSCA+SOX2+) markers. These cells resisted castration in vitro by upregulating the expression of AR, PSA, and proliferation markers KI67 and PCNA. The intermediate cells had high tumorigenicity in vivo, forming tumors in immunodeficient NCG mice in a month without any genetic modification or co-transplantation with embryonic urogenital sinus mesenchyme (UGSM) cells. We named these cells human castration-resistant intermediate prostate cancer stem cells or CriPCSCs and defined the xenograft model as patient primary cell-derived xenograft (PrDX). Human CriPCSCs resisted castration in vitro and in vivo by upregulating AR expression. Furthermore, human CriPCSCs differentiated into amplifying adenocarcinoma cells of luminal phenotype in PrDX tumors in vivo, which can dedifferentiate into CriPCSCs in vitro. Conclusions: Our study identified and established methods for culturing human CriPCSCs, which had high tumorigenicity in vivo without any genetic modification or UGSM co-transplantation. Human CriPCSCs differentiated into amplifying adenocarcinoma cells of luminal phenotype in the fast-growing tumors in vivo, which hold the potential to dedifferentiate into intermediate stem cells. These cells resisted castration by upregulating AR expression. The human CriPCSC and PrDX methods hold significant potential for advancing prostate cancer research and precision medicine.

Intermediate basal cell population in prostate homeostasis and cancer initiation

The Cell Fates of Intermediate Cell Population in Prostate Development

JAK/STAT signaling maintains an intermediate cell population during prostate basal cell fate determination

Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells

The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.

Identification of a basal stem cell subpopulation in the prostate via functional, lineage tracing and single-cell RNA-seq analyses

Identification of a Zeb1 Expressing Basal Stem Cell Subpopulation in the Prostate

Nkx3.1 and P27kip1cooperate in Proliferation Inhibition and Apoptosis Induction in Human Androgen–Independent Prostate Cancer Cells

Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips

Prostate luminal progenitor cells: from mouse to human, from health to disease

Prostate Sphere-forming Stem Cells Are Derived from the P63-expressing Basal Compartment

Pten deletion leads to the expansion of a prostatic stemprogenitor cell subpopulation and tumor initiation

Prostate Luminal Progenitor Cells in Development and Cancer

Stem Cell and Neurogenic Gene-Expression Profiles Link Prostate Basal Cells to Aggressive Prostate Cancer

Relationship between the Expression of Estrogen Receptor α and Basal Cell Dedifferentiation in Benign Prostatic Hyperplasia

Mutational and Transcriptomic Landscapes of a Rare Human Prostate Basal Cell Carcinoma.

Human intermediate prostate cancer stem cells contribute to the initiation and development of prostate adenocarcinoma

Transcriptome Profiling Links the Intrinsic Properties of Human Prostate Basal Cells to Prostate Cancer Aggressiveness.

Deep RNA-Seq Analysis Reveals Unexpected Features of Human Prostate Basal Epithelial Cells

Regenerative potential of prostate luminal cells revealed by single-cell analysis

A basal cell defect promotes budding of prostatic intraepithelial neoplasia